Acquires Kartos Therapeutics for $450M upfront; Up to $1.3B in milestones
Acquisition adds navtemadlin, an investigational oral MDM2 inhibitor in Phase III for myelofibrosis as an add-on therapy to standard of care ruxolitinib. - POIESIS Phase III registrational trial is designed to enroll >600 patients across >250 sites; top-line data expected in 2027. - Deal expected to close by end of Q3